Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT00771914

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

Sponsor: American College of Clinical Pharmacy

Interventions Aspirin Both Aspirin and Lovaza Lovaza Placebo

Updated 6 times since 2017 Last updated: Oct 31, 2012 Started: Nov 30, 2008 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00771914, this PHASE1/PHASE2 trial focuses on Increased Drug Resistance and remains completed. Sponsored by American College of Clinical Pharmacy, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American College of Clinical Pharmacy
Cornell University
GlaxoSmithKline
University of Rochester

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States